WASHINGTON — Medicare has already received more than 4,300 comments on its recent proposal to limit coverage for Biogen’s controversial Alzheimer’s drug Aduhelm, and other similar drugs. But most aren’t from drug makers, Alzheimer’s advocacy groups, or even neurologists.
They’re from two unexpected letter writing campaigns. Continue to STAT+ to read the full story…